193 related articles for article (PubMed ID: 24892551)
1. Role of leukocyte cell-derived chemotaxin 2 as a biomarker in hepatocellular carcinoma.
Okabe H; Delgado E; Lee JM; Yang J; Kinoshita H; Hayashi H; Tsung A; Behari J; Beppu T; Baba H; Monga SP
PLoS One; 2014; 9(6):e98817. PubMed ID: 24892551
[TBL] [Abstract][Full Text] [Related]
2. Leukocyte cell-derived chemotaxin 2 regulates epithelial-mesenchymal transition and cancer stemness in hepatocellular carcinoma.
Chu TH; Ko CY; Tai PH; Chang YC; Huang CC; Wu TY; Chan HH; Wu PH; Weng CH; Lin YW; Kung ML; Fang CC; Wu JC; Wen ZH; Lee YK; Hu TH; Tai MH
J Biol Chem; 2022 Oct; 298(10):102442. PubMed ID: 36055405
[TBL] [Abstract][Full Text] [Related]
3. Identification of the leukocyte cell-derived chemotaxin 2 as a direct target gene of beta-catenin in the liver.
Ovejero C; Cavard C; Périanin A; Hakvoort T; Vermeulen J; Godard C; Fabre M; Chafey P; Suzuki K; Romagnolo B; Yamagoe S; Perret C
Hepatology; 2004 Jul; 40(1):167-76. PubMed ID: 15239100
[TBL] [Abstract][Full Text] [Related]
4. The tumor suppressor function of LECT2 in human hepatocellular carcinoma makes it a potential therapeutic target.
Ong HT; Tan PK; Wang SM; Hian Low DT; Ooi LL; Hui KM
Cancer Gene Ther; 2011 Jun; 18(6):399-406. PubMed ID: 21394108
[TBL] [Abstract][Full Text] [Related]
5. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
[TBL] [Abstract][Full Text] [Related]
6. Hepatic cancer stem cell marker granulin-epithelin precursor and β-catenin expression associate with recurrence in hepatocellular carcinoma.
Cheung PF; Cheung TT; Yip CW; Ng LW; Fung SW; Lo CM; Fan ST; Cheung ST
Oncotarget; 2016 Apr; 7(16):21644-57. PubMed ID: 26942873
[TBL] [Abstract][Full Text] [Related]
7. Regulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system.
Latasa MU; Salis F; Urtasun R; Garcia-Irigoyen O; Elizalde M; Uriarte I; Santamaria M; Feo F; Pascale RM; Prieto J; Berasain C; Avila MA
PLoS One; 2012; 7(12):e52711. PubMed ID: 23285165
[TBL] [Abstract][Full Text] [Related]
8. Expression of NKG2D ligands is downregulated by β-catenin signalling and associates with HCC aggressiveness.
Cadoux M; Caruso S; Pham S; Gougelet A; Pophillat C; Riou R; Loesch R; Colnot S; Nguyen CT; Calderaro J; Celton-Morizur S; Guerra N; Zucman-Rossi J; Desdouets C; Couty JP
J Hepatol; 2021 Jun; 74(6):1386-1397. PubMed ID: 33484773
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice.
Anson M; Crain-Denoyelle AM; Baud V; Chereau F; Gougelet A; Terris B; Yamagoe S; Colnot S; Viguier M; Perret C; Couty JP
J Clin Invest; 2012 Feb; 122(2):586-99. PubMed ID: 22251704
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of VEGF165/VEGFR2-dependent signaling by LECT2 suppresses hepatocellular carcinoma angiogenesis.
Chen CK; Yu WH; Cheng TY; Chen MW; Su CY; Yang YC; Kuo TC; Lin MT; Huang YC; Hsiao M; Hua KT; Hung MC; Kuo ML
Sci Rep; 2016 Aug; 6():31398. PubMed ID: 27507763
[TBL] [Abstract][Full Text] [Related]
11. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
[TBL] [Abstract][Full Text] [Related]
12. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
13. β-catenin-activated hepatocellular carcinomas are addicted to fatty acids.
Senni N; Savall M; Cabrerizo Granados D; Alves-Guerra MC; Sartor C; Lagoutte I; Gougelet A; Terris B; Gilgenkrantz H; Perret C; Colnot S; Bossard P
Gut; 2019 Feb; 68(2):322-334. PubMed ID: 29650531
[TBL] [Abstract][Full Text] [Related]
14. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
[TBL] [Abstract][Full Text] [Related]
15. Diverse Basis of β-Catenin Activation in Human Hepatocellular Carcinoma: Implications in Biology and Prognosis.
Okabe H; Kinoshita H; Imai K; Nakagawa S; Higashi T; Arima K; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Ishiko T; Yoshizumi T; Beppu T; Monga SP; Baba H; Maehara Y
PLoS One; 2016; 11(4):e0152695. PubMed ID: 27100093
[TBL] [Abstract][Full Text] [Related]
16. Expression of β-catenin protein in hepatocellular carcinoma and its relationship with alpha-fetoprotein.
Ren YJ; Huang T; Yu HL; Zhang L; He QJ; Xiong ZF; Peng H
J Huazhong Univ Sci Technolog Med Sci; 2016 Dec; 36(6):846-851. PubMed ID: 27924522
[TBL] [Abstract][Full Text] [Related]
17. Targeting β-catenin in hepatocellular cancers induced by coexpression of mutant β-catenin and K-Ras in mice.
Tao J; Zhang R; Singh S; Poddar M; Xu E; Oertel M; Chen X; Ganesh S; Abrams M; Monga SP
Hepatology; 2017 May; 65(5):1581-1599. PubMed ID: 27981621
[TBL] [Abstract][Full Text] [Related]
18. Lect2 Controls Inflammatory Monocytes to Constrain the Growth and Progression of Hepatocellular Carcinoma.
L'Hermitte A; Pham S; Cadoux M; Couchy G; Caruso S; Anson M; Crain-Denoyelle AM; Celton-Morizur S; Yamagoe S; Zucman-Rossi J; Desdouets C; Couty JP
Hepatology; 2019 Jan; 69(1):160-178. PubMed ID: 30070727
[TBL] [Abstract][Full Text] [Related]
19. Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin.
Tao J; Xu E; Zhao Y; Singh S; Li X; Couchy G; Chen X; Zucman-Rossi J; Chikina M; Monga SP
Hepatology; 2016 Nov; 64(5):1587-1605. PubMed ID: 27097116
[TBL] [Abstract][Full Text] [Related]
20. Leukocyte cell-derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitment.
Chen CK; Yang CY; Hua KT; Ho MC; Johansson G; Jeng YM; Chen CN; Chen MW; Lee WJ; Su JL; Lai TC; Chou CC; Ho BC; Chang CF; Lee PH; Chang KJ; Hsiao M; Lin MT; Kuo ML
Hepatology; 2014 Mar; 59(3):974-85. PubMed ID: 24114941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
